Current evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome

Background. Atypical haemolytic uraemic syndrome (aHUS) is a rare, life-threatening disorder for which eculizumab is the only approved treatment. Life-long treatment is indicated; however, eculizumab discontinuation has been reported. Methods. Unpublished authors’ cases and published cases of eculiz...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Clin Kidney J
Asıl Yazarlar: Macia, Manuel, de Alvaro Moreno, Fernando, Dutt, Tina, Fehrman, Ingela, Hadaya, Karine, Gasteyger, Christoph, Heyne, Nils
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2017
Konular:
Hereditary Kidney Disease
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5466111/
https://ncbi.nlm.nih.gov/pubmed/28621343
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ckj/sfw115
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller